Abstract: Embodiments relate to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. Embodiments relate to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives.

Abstract: Disclosed is a smokeless cigarette system comprising a reusable cigarette tube and a nicotine stick which can be discarded after use. The nicotine stick comprises a depot filter charged with a nanobead solution and nicotine and flavor substances attached thereto or incorporated therein, and a mouthpiece filter, which are joined together and produced at the factory stage. The disclosed smokeless cigarette is particularly suited for use in non-smoking areas to prevent stress caused by nicotine withdrawal and as a cigarette substitute, but can also be used in different types of cigarettes with varied dosage strengths to ensure gentle nicotine withdrawal and smoke disintoxication. Neither the environment nor other persons are harmed of put at risk by this system by either passive smoking or the generation of odour. The system can be handled in a simple and unproblematic manner since no heat source or heating systems are required.

Abstract: Embodiments relate to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. Embodiments relate to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives.

Abstract: The invention comprises an apparatus 10 and a method 100 for purifying biomolecules 28. Magnetizable particles 35 and a group of magnetizable pins 40 are used for binding biomolecules 28 to the magnetizable particles 35 using a binding buffer 30b, and for transferring the magnetizable particles 35 forming a particle-biomolecule complex 36. The apparatus 10 comprises an incubation unit 60 that allows for an upscaling of a maximum volume of a sample material. Furthermore the apparatus 10 comprises counter magnets 50 which are arranged on cavities 20. Solutions 30 comprising the biomolecules 28 and the magnetizable particles 35 are disposed in the cavities. The use of counter magnets 50 improves the quality of an eluate. Furthermore the invention comprises a system 800 and a method 900 for a diagnostically purifying of biomolecules 28.

Abstract: The invention relates to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. The invention relates to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives.

Abstract: The invention relates to a novel smokeless cigarette system comprising two parts: a reusable cigarette tube (1) and a nicotine stick (5) which can be discarded after use. The nicotine stick (5), comprising a deposit filter (2) that is charged with a nanobead solution (4) and nicotine and flavour substances attached thereto or incorporated therein, and the mouthpiece filter (3) are joined together and produced at the factory stage. All parts closely reproduce a cigarette as detailed as possible in terms of their outer appearance, design, dimensions, draw resistance during use, taste and nicotine absorption. According to the invention, the smokeless cigarette is particularly suited for use by smokers in non-smoking areas in order to prevent stress caused by nicotine withdrawal and as a cigarette substitute, but can also be used in different types of cigarettes with varied dosage strengths to ensure a gentle (slow) nicotine withdrawal and smoker disintoxication.

Abstract: Embodiments relate to methods and formulations of buffers used for isolating, purifying, and recovering long-chain and short-chain nucleic acids. The areas of application of the inventive method include all laboratories engaged in isolating nucleic acids. In one embodiment a solution containing a nucleic acid is prepared with additives containing monovalent and multivalent cations and, optionally, an alcohol and/or additional additives. The solution is contacted with a solid phase, the solid phase is optionally washed, and the nucleic acid is removed. The solution may contain multivalent and/or monovalent cations and may contain an alcohol. The solution in certain embodiments has a pH between 7 and 10. Ammonium chloride, sodium chloride and/or potassium chloride may be used as monovalent salt components. Magnesium chloride, calcium chloride, zinc chloride and/or manganese chloride may be used as multivalent salt components.

Abstract: The invention relates to a means of therapy and prophylaxis of Diabetes mellitus Type 1 and Type 2. Fields of application of the invention are medicine and the pharmaceutical industry. The invention has the objective of developing a new kind of means for therapy and prophylaxis of Diabetes mellitus. The means according to the invention entails physically and/or chemically activated minerals and, if applicable, further substances. Preferred substances are heulandite/klinoptilolith, natrolith or thomsonite. The particle diameter preferably below 5 ?m.

Abstract: The invention comprises an apparatus 10 and a method 100 for automatically lysing, extracting and purifying biomolecules 28. As the central technology for purifying the biomolecules magnetizable particles 35 and an adapted magnet device 40 are used for binding and transferring the particles 35. The apparatus 10 comprises a highly efficient incubation unit 60 with options for upscaling the maximum sample amount. Furthermore the apparatus 10 in particular comprises a group of magnetizable pins 40 as transport magnets and furthermore counter magnets 50 which are arranged on the cavities 20, in which solutions 30 with the biomolecules 28 to be lysed and magnetizable particles 35 are disposed. The use of counter magnets 50 improves the quality of the eluate. Furthermore the invention comprises a fully automatic system 800 and a method 100 for controlling the process steps and the selection of the reagents and the aids (e.g.

Abstract: The object of the invention is formulations and methods without chaotropic components for the isolation of nucleic acids with binding to a solid phase, in particular of DNA, from arbitrary complex starting materials containing a lysis/binding buffer system manifesting at least one anti-chaotropic salt component, the concentration of the anti-chaotropic salt components being between 0.001 mM and 0.1 M, preferably 0.1 mM, and further a solid phase and washing and elution buffers which are known per se. The lysis/binding buffer system can exist as an aqueous solution or as a solid formulation in ready-to-use reaction vessels. As a solid phase, all carrier materials applied for isolation by means of chaotropic reagents can function, preferably glass fibre fleeces, glass membranes, silicone carriers, ceramics, zeoliths or materials possessing negatively functionalised surfaces or manifesting chemically modified surfaces which can be converted to a negative charging potential.

Abstract: The invention relates to a new method for the control of enzymatic duplication of nucleic acids by the section via incomplete complementary strands. Fields of application of the invention are research, medical practice, gene-based analytics of biotechnological, agricultural and foodstuff products as well as criminology.

Abstract: The invention relates to novel formulations of buffers used for isolating, purifying and recovering long-chain and short-chain nucleic acids. The areas of application of the inventive method include all laboratories engaged in isolating nucleic acids, such as laboratories used in forensic medicine, food diagnosis, medical diagnosis, molecular biology, biochemistry, genetic engineering and all other related fields. The inventive method is characterized in that the solution containing the nucleic acid is prepared with additives whereby containing monovalent and multivalent cations as well as an alcohol and, optionally, additional additives. The solution is subsequently brought into contact with the solid phase, whereupon the support is optionally washed, and the nucleic acid is removed from the solid phase or the solution optionally contains multivalent and/or monovalent cations, optionally one alcohol, and optionally contains additional additives, and a specific pH value is set between 7 and 10.

Abstract: The invention relates to a method for detecting increased susceptibility to tumours by specifically detecting a polymorphism in the position 354 A ? G in the exon 12 of the human murine double minute-2 (MDM2) gene. Said polymorphism represents a hereditary marker for increased risk of cancer in humans. The invention also relates to the use of said tumour susceptibility marker for developing in vitro and in vivo test systems which integrate said markers, in a specific manner, into diagnostic, prognostic and possibly therapeutic methods.

Abstract: The invention relates to ELISA kits for detecting pro-collagenase 3 and activated collagenase 3 in body fluids, especially in human serum and synovial fluid, and in cell culture supernatants, and monoclonal antibodies which specifically recognise said antigens. Said ELISA kit comprises the following separately packed elements: a) a solid carrier comprising monoclonal antibodies which are bound thereto and sensitively and specifically bind human procollagenase 3 or activated collagenase 3; b) human recombinant procollagenase 3 or activated collagenase 3 as a standard for the quantitative determination of said enzyme; c) a buffer for producing a standard series of the recombinant collagenase 3; d) a buffer for diluting the body fluids to be analysed; e) a conjugate which is marked in such a way that it can be detected and which binds to collagenase 3; and f) a substrate which enables the visualisation of said conjugate which is marked in such a way that it can be detected.

Abstract: The invention relates to standard reaction areas containing complex, storage-stable reagent formulations and thus suited to acceptance and, if need be, storage of complex liquid patient samples, thereafter to be examined for the existence of pathogenic nucleic acids (bacteria, viruses etc.). Preferably, the reaction areas manifest complex, storage-stable reagent formulations permitting detection and quantitative isolation of viral and bacterial nucleic acids in a test kit, even in the existence of extremely low copy numbers from a complex biological sample. At the same time, a simple archiving system for the clinically relevant nucleic acids can be provided. Thanks to the use of said reaction areas containing the complex, storage-stable reagent formulations, necessary process steps of sample handling are drastically reduced and thus potential risks of infection and risks of contamination distinctly lowered.

Abstract: The invention relates to a new multiwell filtration plate for high throughput applications in nucleic acid technology, preferably in a 96-well or 384-well format, consisting of two individual parts, which are firmly and tightly connected together. The upper part of the plate is a sample holder 1 for holding a sample to be filtered. The lower part of the plate is an outlet part with a filter insert for receiving a sample from the sample holder part and filtering the, sample through the filter insert.

Abstract: The subject of the invention are formulations not containing chaotropic components for isolating nucleic acids with binding to a solid phase, in particular of DNA, from optional complex starting materials and quantities containing a lysis/binding buffer system which comprises at least one antichaotropic salt component, a solid phase and wash and elution buffers known as such. The lysis/binding buffer system may be an aqueous solution or a solid formulation in reaction vessels ready for use. All carriers used for isolation by means of chaotropic reagents, preferably glass fiber mats, glass membranes, silica carriers, ceramics, zeolites or materials showing negatively functionalised surfaces or chemically modified surfaces which may be converted to a negative charge potential may serve as a solid phase.

Abstract: The invention relates to a material for the complex manipulation of nucleic acids as a platform technology for developing integrative, fully automatic systems for nucleic acid analysis. The inventive support material for complex nucleic acid analysis is characterised in that at least one covalently bonded layer is located on the surface, said layer bearing at least two different functional groups which are statistically distributed on the surface. At least one of the functional groups is negatively charged and at least one other functional group is positively charged or chemically reactive or has both of these properties.

Abstract: The invention relates to surface-modified supporting materials for binding biological materials, wherein the surface of said materials carries negatively charged functional groups.

Abstract: Disclosed is a method to detect clinically relevant mutations of the DNA sequence of the KI-ras oncogene in stool DNA, its use and a testkit based thereon for early diagnosis of tumors, especially tumors of the pancreas and the colon. According to the invention, the method of detection is distinguished by extraction of genomic DNA from stool samples in a series of cleaning operations designed to eliminate inhibitor substances, and by base-complementary hybridization reaction by adding six different oligonucleotides with a defined complementarity to the clinically relevant mutated sequence fragments of the KI-ras gene.